Despite Early Approval Of Omidubicel, Analyst Says Longer-Term Financial Overhang Remains For Gamida Cell

  • On Monday, Gamida Cell Ltd GMDA received Omidubicel approval two weeks before the PDUFA date of 1 May.
  • Soon after, Gamida Cell announced an equity offering of 17.5 million shares and accompanying warrants to purchase 17.5 million shares at $1.30 for approximately $22.8 million in gross proceeds.
  • Needham analyst has reduced the price target to $6 from $8 with a Buy rating to account for dilution and expectation of a more conservative launch trajectory.
  • Needham writes that the approval is warranted, given robust Phase 3 results and clear unmet needs. 
  • It also says that the approval is a solid testament to Gamida's ability to execute a complex cellular therapeutic, putting any doubts on drug product execution at bay.
  • Initial pricing was quoted at $338,000, higher than Needham's expectation of ~$200,000 and more in line with typical cellular therapeutics. 
  • The analyst notes that the clear clinical benefits of Omisirge, particularly in patients who cannot find a match, justify the cellular therapeutic price point. But there are also concerns that the high price point may negatively impact adoption and coverage. 
  • It expects the high price may dampen uptake outside of initial unmatched patients and those slated to receive cord blood.
  • Needham has reduced the expected market penetration and expects a longer ramp in patients receiving a haplo or unrelated match. 
  • Overall, a peak penetration forecast that assumes Omisirige is used in a little under 2,000 patients each year.
  • With previously announced restructuring, equity raise can support operations at least till year-end 23. However, a longer-term financial overhang remains. 
  • Price Action: GMDA shares are up 1.19% at $1.62 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!